9575Background: Treatment of melanoma with checkpoint blockade immunotherapy brings potential for long-term freedom from progression. However, responses to immunotherapy are heterogeneous, and improving outcomes remains a critical need. We explored whether gut microbiota may modulate response to immunotherapy. Methods: Stool was collected from 26 stage 3-4 melanoma patients at NYU Langone Health, prior to immunotherapy (Ipi, Nivo, Ipi+Nivo, or Pembro). We conducted 16S rRNA gene sequencing on Illumina MiSeq, followed by the QIIME2 Deblur workflow to characterize taxonomic composition. We examined bacterial community α- and β-diversity, and taxon abundance, in relation to time to disease progression, using survival methods and adjusting for age and sex. Results: During follow-up (range: 3-18 months), 12 patients progressed. Higher community diversity was marginally associated with lower risk of progression (Shannon index HR = 0.40; 95% CI = 0.14-1.17; p = 0.09). Overall community composition was also margi...